This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: H35.59 | Special Copayment Reduction: V209 | Coverage period: 5 years |
| B. Synonyms | Inherited retinal dystrophy (IRD), inherited retinal dystrophy (unspecified), hereditary retinal degeneration, unclassified retinal dystrophy |
| C. Adult onset | Low-to-moderate likelihood of first onset in adulthood — varies with the spectrum of included diseases; some congenital, some adult onset |
| 1. History | Clinical classification began in the 19th century; more than 300 genes discovered since the introduction of NGS; H35.59 is the residual unclassified category |
| 2. Causes | Variants in more than 300 genes related to photoreceptors, RPE, cilia, and the visual cycle; molecular cause unidentified in 20~30% |
| 3. Genetics | Various, including autosomal recessive (AR), autosomal dominant (AD), and X-linked (XL); panel NGS is the standard for classification |
| 4. Epidemiology | Overall IRD prevalence about 1/2,000~1/3,000; RP most common; about 50 per 100,000 when retinitis pigmentosa is included |
| 5. Pathophysiology | Deficiency of proteins required to maintain photoreceptor structure, function, and survival → dual degeneration of photoreceptors and RPE → vision loss |
| 6. Symptoms | Night blindness, peripheral visual field constriction, color vision abnormalities, reduced visual acuity; age of onset and rate of progression vary by genotype |
| 7. Signs | Fundus abnormalities, RPE changes, reduced ERG; refer to genotype-specific fundus patterns |
| 8. Screening | ERG + fundus photography in those with a family history; active IRD panel genetic testing recommended |
| 9. Diagnosis | Clinical phenotype + retinal imaging (FAF, OCT) + ERG + gene panel NGS; H35.59 applied when a specific diagnosis cannot be made |
| 10. Treatment | Vitamin A (specific RP types), DHA, low-vision rehabilitation; evaluation for enrollment in genotype-specific gene therapy clinical trials |
| 11. Prognosis | Broad spectrum depending on gene and phenotype; most progress slowly; quality of life maintained with early rehabilitation |
| 12. Prevention | Genetic counseling; UV protection; excess vitamin A contraindicated (some subtypes); regular follow-up, ongoing evaluation of clinical trial eligibility |
| References | 10 key references with PMIDs |
Inherited Retinal Dystrophy (IRD) is not a single disease but a categorical diagnosis encompassing the entire group of disorders in which photoreceptors or the retinal pigment epithelium (RPE) degenerate due to genetic causes. From the mid-19th century, clinicians began describing retinitis pigmentosa (RP), characterized by night blindness, peripheral visual field constriction, and bone spicule pigmentation, and subsequently various subtypes were named, including macular dystrophy, cone-rod dystrophy, and choroidal dystrophy.
With advances in molecular genetics in the late 20th century, the first causative gene of RP (the rhodopsin gene, RHO) was identified in 1990, and subsequently numerous genes, including PRPF31, USH2A, RPGR, ABCA4, CNGB1, and EYS, were identified as causes of IRD. As next-generation sequencing (NGS)-based gene panels were introduced into clinical practice in the 2010s, more than 300 IRD-related genes became known, and the RetNet (Retinal Information Network) database currently lists more than 300 genes.
ICD-10 code H35.59, "hereditary retinal dystrophy, unspecified," is a residual category for cases not classified into a specific subtype despite clinical and genetic testing, and it is applied provisionally when the diagnostic process is still under way or the causative gene could not be identified with current technology. With advances in whole genome sequencing (WGS) and RNA analysis technologies, the proportion of patients in this category is gradually decreasing.
Inherited retinal dystrophies are caused by variants in hundreds of genes involved in maintaining retinal function and structure. These genes are broadly divided into the following functional categories: ① phototransduction-related (RHO, PDE6A, PDE6B, CNGA1, CNGB1, GNAT2, etc.), ② visual cycle-related (RPE65, RDH12, RLBP1, RGR, etc.), ③ photoreceptor outer segment structure and maintenance (PRPH2, ROM1, etc.), ④ cilia and photoreceptor inner segment (ciliopathy)-related (RPGR, RPGRIP1, CEP290, CC2D2A, etc.), ⑤ transcription factors and development (CRX, NRL, NR2E3, etc.), ⑥ RNA splicing (PRPF3, PRPF4, PRPF8, PRPF31, RP9, etc.), ⑦ cell polarity and cytoskeleton (USHER gene group: MYO7A, USH2A, CDH23, etc.).
A molecular genetic cause is identified in about 70~80% of all IRD patients, while the remaining 20~30% are not explained by variants in currently known IRD genes. Some of the unresolved patients are presumed to have noncoding variants in known genes (deep intronic, regulatory), structural variants (CNV), or variants in new genes not yet discovered. This category is the main target for H35.59.
The same clinical phenotype can be caused by a single gene variant (e.g., PRPF31 variants causing RP or age-related retinal abnormalities), and conversely there is phenotypic overlap in which the same gene causes different clinical syndromes (e.g., CEP290 variants causing one of LCA, BBS, or Joubert syndrome); when a specific diagnosis cannot be assigned, H35.59 is applied.
The inheritance patterns of IRD are diverse. Taking retinitis pigmentosa (RP) as the reference, autosomal recessive (AR-RP, about 20~25%), autosomal dominant (AD-RP, about 30~40%), X-linked (XL-RP, about 10~15%), both-parent carrier (digenic RP, rare), and mitochondrial inheritance (rare) are known. In macular dystrophies, autosomal dominant inheritance is relatively common, and LCA/EOSRD is mainly autosomal recessive.
Sporadic cases without a family history can arise from new mutations (de novo variants), hidden autosomal recessive inheritance, dominant inheritance with incomplete penetrance, and so on. Some dominantly inherited IRD genes (PRPF31, RP1, etc.) have incomplete penetrance, so whether the disease develops may differ within a family even among those carrying the same variant.
Panel NGS-based genetic diagnosis is the standard molecular diagnostic method for IRD. Panels currently offered by Blueprint Genetics, Invitae, GeneDx, and others include 176~935 IRD-related genes, and the overall diagnostic yield is about 50~85% depending on panel size and disease subtype. The diagnostic yield is highest in autosomal recessive IRD (about 75~83%) and lowest in autosomal dominant IRD (about 50%). When a variant is identified on only one allele, deep intronic variants or WES/WGS are additionally considered.
The combined prevalence of all IRDs is estimated at about 1/2,000~1/3,000, of which retinitis pigmentosa (RP) is the most common form, accounting for about half of all IRDs. The prevalence of RP is about 1/3,500~1/4,000. Macular dystrophies (Stargardt disease, Best disease, North Carolina macular dystrophy, etc.) are the second largest category, and LCA/EOSRD (about 1/30,000~1/80,000), choroidal dystrophies, cone dystrophies, cone-rod dystrophies, and others make up the rest.
Sex distribution differs by inheritance pattern. XL-RP mainly affects males, and female carriers sometimes show mild fundus changes. AR-RP and AD-RP occur without sex differences. Age of onset varies greatly, from congenital (LCA) to adult onset (some AD-RP, macular dystrophies). AR-IRD prevalence tends to be higher in populations with a high frequency of consanguineous marriage.
The "unspecified" hereditary retinal dystrophy category to which code H35.59 applies accounted for a substantial share of diagnoses before the introduction of gene panels, but its proportion is now steadily declining with advances such as WGS and RNA analysis. Clinically, this code is applied provisionally to patients whose confirmation is under way or who are awaiting reclassification.
The common final pathway of inherited retinal dystrophies is the progressive death of photoreceptors (cones and rods) and RPE cells, but the molecular pathways leading there vary by causative gene. They can be broadly classified into three higher-level mechanisms.
First, abnormalities of the phototransduction pathway. Misfolding of photoreceptor proteins such as rhodopsin (RHO) induces endoplasmic reticulum stress (ER stress) and the unfolded protein response (UPR), leading to rod apoptosis. PDE6 subunit deficiency causes failure of cGMP breakdown, so that cGMP accumulates abnormally, causing calcium overload and cell death within photoreceptors. Second, abnormalities of cell structure and ciliary function. Deficiency of cilia-related proteins such as RPGR, CEP290, and RPGRIP1 impairs protein transport to the photoreceptor outer segment, and when outer segment structure cannot be maintained, photoreceptors gradually degenerate. PRPH2 (peripherin-2) deficiency impairs formation of photoreceptor disc membranes.
Third, RPE dysfunction. RPE cells play roles essential for photoreceptor survival, including phagocytosis of photoreceptor outer segments, retinoid metabolism, and supply of oxygen and nutrients. MERTK gene variants impair RPE phagocytic function, and RPE65 deficiency blocks the visual cycle. Loss of RPE function secondarily causes nutrient deficiency and oxidative stress in photoreceptors, leading to photoreceptor degeneration. Secondary cone degeneration occurs from oxidative overload after rod loss and is the reason central vision in RP is relatively preserved until the late stage before declining.
The symptoms of inherited retinal dystrophies vary greatly depending on the included disease subtype and the causative gene. In rod-predominant dystrophies (RP, etc.), night blindness appears as an early symptom, manifesting as reduced ability of visual adaptation in dark environments. Peripheral visual field constriction then progresses gradually, typically forming "tunnel vision," and ultimately central vision is also lost.
In cone-predominant dystrophies or macular dystrophies, reduced central vision, color vision abnormalities, and photophobia are early symptoms. Difficulty reading, reduced color discrimination, and worse vision in bright light are characteristic. In cone-rod dystrophy, both cones and rods are affected, so reduced central vision and night blindness appear simultaneously from the early stage. Syndromic IRDs in which retinal dystrophy is accompanied by sensorineural hearing loss, such as Usher syndrome, also show abnormalities on hearing tests.
Age of onset varies greatly depending on the disease spectrum, from congenital (LCA) to adult onset in the 30s~50s. In some AD-RP, symptoms first appear in the 40s~50s. In Best macular dystrophy (BEST1 variants), vitelliform macular lesions appear in childhood, but vision may be maintained for decades. Abnormalities may be found on ERG or retinal imaging before symptoms are subjectively recognized, so in those with a family history the diagnosis is sometimes made at the asymptomatic stage.
The classic fundus findings of retinitis pigmentosa (RP) are the triad of peripheral bone spicule pigmentation, retinal arteriolar attenuation, and waxy pallor of the optic disc. However, in early or atypical RP, not all of these findings may be present, and some show the "sine pigmento" type, with only reduced retinal function without peripheral pigmentation. Cystoid macular edema (CME) is observed in about 20~40% of RP patients and contributes to reduced central vision.
In macular dystrophies, the pattern of macular atrophy varies by genotype. Stargardt disease is characterized by yellow macular flecks, hypoautofluorescent macular lesions on FAF, and a dark choroid on FAG. Best disease is characterized by early vitelliform lesions and late satellite and atrophic lesions, and reduced EOG (electro-oculogram) is a diagnostic criterion. Cone dystrophy is characterized by "bull's eye" macular atrophy.
On full-field ERG, in rod-predominant dystrophies the dark-adapted responses are lost first, and in cone-predominant dystrophies the light-adapted responses decrease first. This pattern is the key basis for clinical subtype classification. On OCT, thinning of the photoreceptor layer (ellipsoid zone), RPE atrophy, and inner retinal changes are observed. Visual field testing identifies defect patterns including annular scotoma, peripheral visual field constriction, and central scotoma.
The main target of screening for inherited retinal dystrophies is the at-risk group with a family history of affected members. In children and adolescents with a family history, at least fundus examination, visual acuity testing, and color vision testing are performed annually, with ERG added when there is clinical suspicion. Regular eye examinations are also recommended for adults with a family history. In the IRD at-risk group, gene panel NGS enables molecular diagnosis even before clinical symptoms appear and provides essential information for evaluating treatment clinical trial eligibility and for genetic counseling.
Newborn screening of the general population is not currently performed as standard, but newborn genetic diagnosis may be considered in families in which variants in ciliopathy-related genes (e.g., the BBS gene group) have been identified. Full-field electroretinography (ERG) is the key test for screening and functional assessment, and abnormal findings sometimes precede fundus findings, making it useful for early diagnosis. FAF is an imaging screening tool suitable for noninvasively mapping areas of retinal dysfunction.
Gene panel NGS testing should be ordered for specific diagnosis in symptomatic patients, and the panel should include at least 100~200 or more IRD-related genes to secure an adequate diagnostic yield. In patients suspected of autosomal recessive disease in whom only a single variant is detected, WES, WGS, or deep intronic variant analysis is additionally performed to increase the diagnostic yield.
The diagnostic approach to unspecified hereditary retinal dystrophy proceeds in multiple steps. Step 1: clinical phenotype classification, dividing cases into clinical subtypes such as rod-predominant, cone-predominant, and mixed dystrophies and macular dystrophies through ERG (full-field, multifocal), visual field testing (Goldmann, Humphrey), color vision testing, fundus photography, FAF, and OCT. Step 2: candidate genes are narrowed down by integrating family history, inheritance pattern (AR/AD/XL), age of onset, and the presence of associated syndromes. Step 3: IRD panel NGS is performed as the first-line molecular diagnostic method.
If no causative variant is identified on panel NGS, testing is expanded to WES or WGS to comprehensively search for single nucleotide variants (SNVs), insertions/deletions (indels), structural variants (CNVs), and deep intronic variants. RNA analysis is useful for confirming the splicing effects of deep intronic variants and for detecting variants that include new exons. If the cause cannot be identified even after all of these steps, H35.59 is used as a provisional code, but reevaluation as technology advances (periodic reanalysis) is recommended.
Important differential diagnoses are non-hereditary retinal degenerations (e.g., autoimmune retinopathy, drug-induced retinal toxicity, vitamin A deficiency retinopathy). Autoimmune retinopathy is differentiated by serum anti-retinal antibody testing, and drug-induced toxicity by taking a medication history. Syndromic IRDs (Usher syndrome, Bardet-Biedl syndrome, Joubert syndrome, etc.) are excluded through evaluation of systemic findings.
Treatment of unspecified hereditary retinal dystrophy currently consists of three main pillars: ① genotype-nonspecific neuroprotective and supportive therapy, ② genotype-specific therapy (when identified), and ③ low-vision rehabilitation. When the genotype is identified, treatment should be switched to genotype-specific therapy where possible.
Vitamin A palmitate (vitamin A palmitate 15,000 IU/day) has been reported to slow the rate of ERG b-wave decline by about 20% in typical retinitis pigmentosa (RP) (Berson 1993 study), and on this basis it is recommended for some RP patients. However, it is contraindicated in ABCA4-related Stargardt disease and PRPH2-variant RP. Some studies suggest that concomitant omega-3 fatty acids (DHA) may have additional benefit, but the evidence is not established. In RP with cystoid macular edema, carbonic anhydrase inhibitors (oral acetazolamide or topical dorzolamide) may help preserve vision.
In terms of gene therapy, voretigene neparvovec (Luxturna) is used for LCA/EOSRD with confirmed RPE65 variants. Numerous other gene therapy clinical trials are under way for RPGR (XL-RP), CNGA3/CNGB3 (achromatopsia), MYO7A (Usher 1B), RLBP1 variants, and others. Low-vision rehabilitation includes electronic magnifiers, screen-reading software, orientation and mobility training (O&M), activities of daily living training, and psychosocial support, and makes the most practical contribution to maintaining independent living in patients with inherited retinal dystrophies.
The prognosis of inherited retinal dystrophies shows a very broad spectrum depending on genotype, inheritance pattern, age of onset, and rate of progression. Typical RP progresses slowly over decades; some patients maintain useful central vision into their 60s~70s, whereas others reach legal blindness in their 30s~40s. RPGR-related XL-RP tends to progress relatively rapidly in males.
Among macular dystrophies, Best disease often shows a relatively stable course for decades, but atrophic changes may progress in old age. In cone dystrophy, central vision is lost rapidly, whereas peripheral vision is preserved for a long time. Syndromic IRDs (Usher syndrome, etc.) are accompanied by hearing impairment and vestibular dysfunction in addition to vision loss, and therefore have a greater impact on overall quality of life. Early diagnosis, active low-vision rehabilitation, and building a social support network are important for maintaining quality of life and the capacity for independent living.
The many gene therapy clinical trials currently under way are expected to lead, within the next 10~20 years, to therapies that halt progression or restore function for specific genotypes. Therefore, regular evaluation of eligibility for clinical trial enrollment, together with efforts to update the molecular diagnosis, should be part of patient management.
The primary preventive measures against the genetic occurrence of inherited retinal dystrophies are genetic counseling and preimplantation genetic testing (PGT) or prenatal diagnosis. When an affected patient in the family is confirmed, genetic counseling is offered to at-risk family members, and the possibility of using assisted reproduction (IVF+PGT-M) is discussed during family planning. Determining a couple's carrier status through carrier testing is the starting point of risk assessment.
For secondary prevention (slowing disease progression), reducing exposure to ultraviolet and high-intensity blue light, wearing UV-blocking glasses, smoking cessation, and a balanced antioxidant diet (containing lutein and zeaxanthin) are recommended. Vitamin A palmitate supplementation has a certain benefit in typical RP but is contraindicated in Stargardt disease and ABCA4-related disease, and should be decided cautiously until the genetic diagnosis is confirmed. Because of the risk of hepatotoxicity, liver function should be monitored during long-term high-dose vitamin A supplementation.
Regular ophthalmic follow-up examinations (at least once a year, or adjusted according to the rate of progression) allow early detection and management of treatable complications such as cystoid macular edema and cataract (posterior subcapsular cataract is common in RP). Systemic factors such as vitamin D deficiency and thyroid dysfunction can also affect retinal health, so an integrated approach that includes overall health management is needed.